Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

Novo Nordisk A/S (NVO) tumbled 22% Tuesday - The company attributed its lowered guidance in part to persistent use of ...

Maziar Mike Doustdar takes over at Novo Nordisk as the company reports weaker earnings than expected on generic challenges to ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Weight gain, low energy and stalled progress at the gym are issues many men face as they get older. But a new wave of ...

Novo Nordisk just lost $100 billion in market value. Here's what the crash means for ResMed — and why investor sentiment may ...

The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...